By Chris Wack
Relmada Therapeutics shares were up 18% at $3.30 after the company reported positive efficacy results for the de novo patients and safety results for all subjects from its Phase 3 registrational trial of REL-1017 in patients with major depressive disorder.
The stock is down 90% in the past 12 months.
The…
Read the full article here